outcomes research

News

Predicting Clinical Outcomes of Patients With High-Risk MCL

06/18/2020

Patients with high-risk mantle cell lymphoma (MCL) biology—defined by blastoid variance, Ki-67 greater than 30%, or high p53 immunohistochemistry expression—are more likely to experience shorter failure-free and...

...

06/18/2020

Journal of Clinical Pathways

News

Assessing Frequency of Secondary Malignancies in Survivors of Hodgkin Lymphoma

06/17/2020

A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.

A single institution study...

06/17/2020

Journal of Clinical Pathways

News

Long-Term Follow-Up of BTK Inhibitor in Symptomatic Treatment-Naïve CLL

06/15/2020

Long-term data from ACE-CL-001 further supports the favorable results of acalabrutinib in phase III studies for patients with symptomatic, treatment-naïve chronic lymphocytic leukemia (CLL). Results of the study...

...

06/15/2020

Journal of Clinical Pathways

News

BTK Inhibitor Effective in Patients With Progressive, High-Risk CLL

06/15/2020

Bruton tyrosine kinase (BTK) inhibitor therapy is effective in patients with chronic lymphocytic leukemia (CLL) who are resistant to prior venetoclax treatment, according to a new study presented at the European...

Bruton...

06/15/2020

Journal of Clinical Pathways

News

Reduced-Intensity Conditioning Regimens for Patients With NHL Undergoing Transplant

06/09/2020

Use of a more intense reduced-intensity conditioning and non-myeloablative conditioning (RIC-NMAC) regimen for allogeneic hematopoietic cell transplant (HCT) in patients with non-Hodgkin lymphoma should be considered...

Use of...

06/09/2020

Journal of Clinical Pathways

News

Final Results of KEYNOTE-100 for Patients With Advanced Ovarian Cancer

06/03/2020

Pembrolizumab monotherapy continues to show modest antitumor activity in patients with recurrent advanced ovarian cancer, according to updated results of the KEYNOTE-100 study presented at the American Society of...

...

06/03/2020

Journal of Clinical Pathways

News

Effective, Less Toxic Treatment Option Identified for Aggressive B-Cell Lymphoma

05/29/2020

Risk-adapted dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) therapy is effective and well tolerated in adults with Burkitt lymphoma regardless of age or...

...

05/29/2020

Journal of Clinical Pathways

News

Practice Patterns, Predictors of Survival for Older Patients With MCL

05/27/2020

A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...

A new...

05/27/2020

Journal of Clinical Pathways

News

Long-Term Outcomes of High-Dose CAR-T Therapy for Relapsed, Refractory CLL

05/12/2020

Chimeric antigen receptor T-cell targeting CD-19 (CAR T-19) may be more effective at a higher dose (5 x 108) than a standard lower dose (5 x 107) in patients with relapsed or refractory chronic lymphocytic leukemia...

...

05/12/2020

Journal of Clinical Pathways

Research in Review

Patients With MCL and a Specific Mutation in Need of Alternative Frontline Therapies

08/21/2017

JCP Editors

Patients with mantle cell lymphoma (MCL) should be stratified based on the status of a specific mutation and considered for alternative first-line therapy, according to a new study published in Blood (online August...

...

08/21/2017

Journal of Clinical Pathways